Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: BioMerieux Appoints New Directors; Exosome Hires Kelly as CFO

Premium

BioMérieux this week appointed of two new independent directors, Agnès Lemarchand and Philippe Gillet. Lemarchand and Gillet are replacing Georges Hibon and Michel Angé, who did not wish to renew their terms on the company's board.

Lemarchand has served as CEO of Industrie Biologique Française, a joint venture between the Rhône-Poulenc group and Institut Mérieux. She has also served as chairman and CEO of Prodical, a subsidiary of the Ciments Français group; and chairman and CEO of the Lafarge group's lime business.

Gillet was a professor of geophysics at the University of Rennes prior to becoming director of l’Ecole Normale Supérieure de Lyon, where he was also a professor of earth sciences. In addition, from May 2007 to April 2010 he served as chief of staff for the French Minister of Higher Education and Research. He subsequently joined l’Ecole Polytechnique Fédérale of Lausanne, where he serves as vice president for academic affairs.


Exosome Diagnostics has named William Kelly as CFO.

Kelly has worked for RepliGen for the past six years, serving as the principal financial officer there for more than five years. He has also served as corporate controller of Haemonetics, and has worked for Deloitte & Touche.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.